TICKERNERD
Menu
ABSIABSIHealthcare · Biotechnology

ABSI Stock Forecast: Absci Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$9.65
+4.10% on the day

The 10 Wall Street analysts covering Absci Corp. hold a median 12-month price target of $15 — +55.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7B
Ticker Nerd rank
35 / 100
Median analyst target
$15
Analysts covering
10
Revenue$318K−46.4% y/y
Operating income−$34.2M
Net income−$33.2M
Free cash flow−$27.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+17.5%
1M
+9.0%
YTD
+176.5%
1Y
+258.7%
From 52W high
−17.0%
From 52W low
+319.6%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Absci Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Growth
53
Accruals
53
Issuance
48
Revisions
40
Value
39
Size
38
Volatility
19
Quality
19

Momentum (96): The shares have been drifting up relative to others.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Oct 25Jan 26Apr 26Jul 26ABSIHigh $17Median $15Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $10Median $15High $17

The green dot is the last close — the median target sits +55.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026LifeSci CapitalInitiatesOutperform—
8 Sept 2026BTIGMaintainsBuy$13 → $16
12 Aug 2026BTIGReiteratesBuy—
12 Aug 2026BTIGReiteratesBuy$13
12 Aug 2026NeedhamReiteratesBuy$11
12 Aug 2026NeedhamReiteratesBuy—
2 July 2026Truist SecuritiesMaintainsBuy$11 → $17
2 July 2026Truist SecuritiesMaintainsBuy—
25 June 2026HC Wainwright & Co.MaintainsBuy$8.00 → $16
25 June 2026HC Wainwright & Co.MaintainsBuy—
24 June 2026BTIGMaintainsBuy—
24 June 2026NeedhamReiteratesBuy—
15 June 2026GuggenheimMaintainsBuy—
4 June 2026Leerink PartnersInitiatesOutperform—
28 May 2026BTIGInitiatesBuy—
8 May 2026Truist SecuritiesMaintainsBuy—
30 Mar 2026NeedhamReiteratesBuy—
25 Mar 2026NeedhamReiteratesBuy—
18 Mar 2026NeedhamReiteratesBuy—
18 Dec 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Absci Corp. returned +258.7% against +16.3% for the S&P 500, dividends included.

ABSI vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26ABSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
6
Fundamentals

Absci Corp. (ABSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.5×

Cheaper than 93% of US stocks

Price / sales
1060.9×

Cheaper than 1% of US stocks

Price / book
6.7×

Cheaper than 14% of US stocks

EV / EBITDA
−12.2×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
−46.4%

Higher than 6% of US stocks

Earnings growth (YoY)
−46.4%

Higher than 11% of US stocks

Gross margin
—
Operating margin
−10741.5%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−57.7%

Higher than 20% of US stocks

Return on assets
−34.1%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Absci Corp. (ABSI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Absci Corp. has a market value of $1.7B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 46.4% year on year.

  • Net income over the same four quarters: −$121.1M, a −7756.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.80.

  • Free cash flow in the twelve months to 30 June 2026: −$109.0M.

  • Shares outstanding: 171.6M.

  • Trailing P/E: −11.5×; forward P/E: −14.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Absci Corp. employs 140 people — $11K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

ABSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABSIAbsci Corp.$1.7B
35
FBRXForte Biosciences, Inc.$1.6B
—
ANABAnaptysBio, Inc.$1.6B
100
TSHATaysha Gene Therapies, Inc.$1.6B
42
INBXInhibrx Biosciences, Inc.$1.6B
26
NVAXNovavax, Inc.$1.7B
56
KRSAKorsana Biosciences, Inc.$1.6B
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Absci Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABSI news & analysis

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Absci Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation and availability of the presentation transcript.

Why it matters — A transcript of Absci's presentation at a major healthcare conference gives ABSI watchers insight into the company's updates and positioning as shared with the investment community.

Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)

Seeking Alpha · 8 Sept 2026positive

Absci Corporation was upgraded to "Buy" following positive interim Phase 1 data for ABS-201 in androgenetic alopecia (AGA). The therapy demonstrated an excellent pharmacokinetic profile enabling infrequent dosing (2-3 injections per 6 months) and strong safety/tolerability in single ascending dose cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in the second half of 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.

Why it matters — Absi watchers would care because the publication's upgrade reflects encouraging early clinical data for ABS-201 and points to several near-term readouts that could shape the company's outlook for its androgenetic alopecia program.

Absci to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Absci Corp. announced that it will participate in upcoming investor conferences, with the announcement originating from Vancouver, Washington and New York. The company will present at these scheduled events.

Why it matters — Investors following ABSI may be interested to learn about the company's scheduled conference participation, which provides an opportunity to hear directly from management.

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

24/7 Wall Street · 18 Aug 2026neutral

On August 14, 2026, Advanced Micro Devices filed its first-ever 13F, disclosing a $1.31 billion equity portfolio concentrated in just six positions. The filing reveals AMD's largest investments and where the company expects AI demand to land next.

Why it matters — An Absci Corp. watcher would care because AMD's disclosed portfolio and AI demand outlook could signal which AI-related companies and sectors may see increased investment and demand.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Zacks Investment Research · 17 Aug 2026positive

Zacks Investment Research highlighted ABSI among four AI-powered drug discovery stocks that use AI platforms to transform drug discovery while advancing proprietary clinical pipelines. The article positions these companies as ones to watch as AI reshapes the pharma industry.

Why it matters — This item is directly relevant to ABSI watchers because it calls attention to the company's AI-driven drug discovery platform and clinical pipeline within a favorable industry trend.

FAQ

Frequently asked questions about ABSI stock

What is the ABSI stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Absci Corp. have a median 12-month price target of $15, with estimates ranging from $10 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABSI stock a buy right now?

Of the 10 analysts covering Absci Corp., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Absci Corp. 35 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABSI?

As at 19 Sept 2026, Absci Corp. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will ABSI stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +55.4% from the last close, and Ticker Nerd's factor model ranks Absci Corp. 35 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABSI stock forecast for 2030?

No analyst covering Absci Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $17 over the next 12 months.

How has ABSI stock performed over the past year?

Absci Corp. returned +258.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Absci Corp. do?

Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas.

What is the latest news on ABSI?

The most recent item we track (Seeking Alpha, 16 Sept 2026): "Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Absci Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation and availability of the presentation transcript.

Company

About Absci Corp.

Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas. Its current pipeline spans programs in immunology, oncology, inflammatory disease, and dermatology, reflecting a platform approach to drug creation rather than a single-product model. The company also collaborates with pharmaceutical and biotechnology partners to support therapeutic discovery and development efforts. Headquartered in Vancouver, Washington, Absci plays a role in the growing market for AI-enabled drug discovery, where data science and biological engineering are combined to improve how new medicines are identified and optimized.

CEO Mr. Sean McClain · 140 employees · United States · https://www.absci.com